What caused MOLN's EPS surge in 2021?

The EPS of Molecular Partners AG (MOLN) experienced a surge in 2021, primarily driven by the company's innovative pipeline of DARPin therapeutics and strategic collaborations. Here's a detailed analysis: 1. **Innovative DARPin Therapeutics**: Molecular Partners has been developing a new class of custom-built protein drugs known as DARPin therapeutics. These drugs are designed to target specific diseases with high precision and efficacy. The company's focus on innovative therapies positions it well for potential breakthroughs in the biopharmaceutical sector. 2. **Strategic Collaborations**: Molecular Partners has formed significant partnerships with major pharmaceutical companies such as Novartis AG, Amgen SA, and AbbVie Inc. These collaborations are aimed at developing, manufacturing, and commercializing DARPin-conjugated radioligand therapies. These partnerships not only enhance the company's financial prospects but also validate its technology and therapeutic approaches. 3. **Clinical Trial Progress**: The company's drug candidates, including Abicipar and MP0420, are advancing through clinical trials. The completion of these trials could lead to significant milestones and potential regulatory approvals, which can positively impact financial performance. For instance, the Phase III clinical trials for Abicipar indicate a potential market for treating neovascular wet age-related macular degeneration and diabetic macular edema. 4. **Market Potential**: The market for DARPin therapeutics is expected to grow significantly, driven by the need for targeted and effective treatments for various diseases. Molecular Partners' innovative pipeline and strategic positioning could lead to substantial market opportunities. In conclusion, Molecular Partners AG's (MOLN) EPS surge in 2021 can be attributed to its innovative DARPin therapeutics, strategic collaborations, clinical trial progress, and the potential for significant market opportunities. These factors collectively contribute to the company's growth prospects and financial performance.